RSSNewsletterSiteMapFeedback

Home · Weather · Forum · Learning Chinese · Jobs · Shopping
Search This Site
China | International | Business | Government | Environment | Olympics/Sports | Travel/Living in China | Culture/Entertainment | Books & Magazines | Health
Home / Health / News Tools: Save | Print | E-mail | Most Read
Genentech: Avastin works for brain cancer
Adjust font size:

Genentech Inc said on Sunday its blockbuster cancer drug, Avastin, showed encouraging results for patients with the most aggressive form of brain cancer. (file photo from Xinhua)

Genentech, the largest U.S. maker of cancer drugs, said 36 percent of patients treated with Avastin alone and 51 percent treated with a combination of the drug and chemotherapy lived without the disease advancing within six months.     

The announcement came after a successful Phase II trial in which bevacizumab showed clear improvements of the patients' survival rate.

In the Phase II trial, the drug, administered alone or with chemotherapy, demonstrated an encouraging six-month survival rate for patients with glioblastoma multiforme (GBM), the most common and aggressive type of brain cancer.

"The findings suggested that at six months, more patients had lived without their cancer advancing when Avastin was administered as a single agent or in combination with chemotherapy, than what we would normally expect," Timothy Cloughesy, the lead investigator for the study, said in a statement.

"These findings exceeded our expectations," said Hal Barron, Genentech's senior vice president of development, in the statement.

Bevacizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Swiss drug maker Roche, which is Genentech's parent company, under the brand name Avastin.

Bevacizumab, approved by the Food and Drug Administration (FDA) in February 2004 for use in colorectal cancer, was the first commercially available angiogenesis inhibitor. This class of drugs stops tumor growth by preventing the formation of new blood vessels. The main side effects of the drug are hypertension and heightened risk of bleeding.

According to the American Cancer Society (ACS), the five-year survival rate for patients with GBM is only three percent, and, more importantly, has not changed in more than 25 years as newer treatments proved ineffective. The ACS also estimates there will be 20,500 new cases of brain cancer and 12,740 brain cancer deaths in 2007.

(Agencies via Xinhua November 19, 2007)

Tools: Save | Print | E-mail | Most Read

Comment
Username Password Anonymous
China Archives
Related >>
Most Viewed >>
-20 Tumors Removed from 'Elephant Man'
-HPV also blamed for oral cancer in men
-Medical Service for Foreigners
-Better nutrition in childhood, higher pay when grown up
-Sick girl receives free surgery in Xinjiang
SiteMap | About Us | RSS | Newsletter | Feedback

Copyright ? China.org.cn. All Rights Reserved E-mail: webmaster@china.org.cn Tel: 86-10-88828000 京ICP證 040089號

主站蜘蛛池模板: 久久中文字幕人妻丝袜| 亚洲欧洲一区二区三区| 花季传媒下载免费安装app| 国产精品.XX视频.XXTV| 97久久精品亚洲中文字幕无码| 女律师的堕落高清hd| 中文字幕在线观看不卡视频| 日韩免费在线观看视频| 亚洲av无码电影网| 欧美日韩一区二区三区麻豆| 亚洲色图激情文学| 男生女生一起差差很痛| 啊老师太深了好大| 西西人体午夜视频| 国产在线拍偷自揄拍无码| 日本一二三精品黑人区| 国产精品男男视频一区二区三区| 99re热这里只有精品| 天天狠狠色综合图片区| √天堂中文在线最新版8下载| 成全视频在线观看免费看| 久久久久久亚洲精品成人| 日韩乱码在线观看| 九九热视频在线播放| 欧美乱xxxxx| 亚洲国产精品久久人人爱| 欧美精品亚洲一区二区在线播放| 亚洲色成人www永久网站| 皇夫被迫含玉势女尊高h| 午夜宅男在线永久免费观看网| 美女黄18以下禁止观看| 四虎永久在线日韩精品观看| 色综合久久久久久久久五月| 国产免费爽爽视频免费可以看| 麻豆国产入口在线观看免费| 国产成人精品动图| 黑人与欧洲性大战| 国产无套粉嫩白浆在线观看| 国产自产视频在线观看香蕉| 国产无套露脸大学生视频| 国产激情视频在线观看首页|